First-line antiretroviral therapy with efavirenz or lopinavir/ritonavir plus two nucleoside analogues: The SUSKA study, a non-randomized comparison from the VACH cohort

Pere Domingo, Ignacio Suárez-Lozano, Ferran Torres, Ramón Teira, José Lopez-Aldeguer, Francesc Vidal, Agustín Muñoz, Pompeyo Viciana, Fernando Lozano, Antonio Vergara, Bernadino Roca, Ma Luisa García Alcalde, Jaime Cosín, Alberto Terrón, Ma José Galindo, Paloma Geijo, Esteban Ribera, Juan Gonzalez, Trinitario Sanchez, Juan Ramón LacalleMyriam Garrido

Research output: Contribution to journalArticleResearchpeer-review

28 Citations (Scopus)

Abstract

Background: Efavirenz and lopinavir/ritonavir are both recommended antiretroviral agents for combination first-line therapy, although information on direct comparisons between them is scarce. A retrospective longitudinal study from the VACH cohort comparing both regimens was performed. Methods: Efficacy was examined comparing time to virological failure, CD4 recovery and clinical progression. Tolerability was examined comparing time to treatment discontinuation for any reason and for toxicity. Survival analysis was conducted using the Kaplan-Meier method, and standard and weighted Cox regression models. Results: A total of 1550 antiretroviral-naive patients starting a two-nucleoside reverse transcriptase inhibitor regimen plus either efavirenz (n = 1159) or lopinavir/ritonavir (n = 391) were included in the study. At baseline, patients starting lopinavir/ritonavir had higher HIV-1 RNA and lower CD4+ cell counts. There was no difference in the adjusted hazards of virological failure [efavirenz versus lopinavir/ ritonavir hazard ratio (HR) = 0.93, 95% confidence interval (CI): 0.77-1.12, P = 0.43], CD4 recovery (HR = 1.11, 95% CI: 0.95-1.30, P = 0.19) and clinical progression (HR = 0.71, 95% CI: 0.39-1.31, P = 0.27). There was an increased risk of discontinuation for any reason or for toxicity for lopinavir/ritonavir (HR = 2.10, 95% CI: 1.40-3.15, P = 0.0003). CD4 recovery with both drugs was also similar in the lowest CD4 strata. A higher risk of early hypertriglyceridaemia was associated with lopinavir/ritonavir-based regimens. Conclusions: Our study suggests similar virological efficacy for efavirenz- or lopinavir/ritonavir-based first-line antiretroviral regimens, but an increased risk of discontinuation because of toxicity in case of lopinavir/ritonavir-based therapy. Immunological outcome appeared similar with both regimens. © The Author 2008. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.
Original languageEnglish
Pages (from-to)1348-1358
JournalJournal of Antimicrobial Chemotherapy
Volume61
Issue number6
DOIs
Publication statusPublished - 1 Jun 2008

Keywords

  • Boosted protease inhibitors
  • Naive patients
  • Non-nucleoside reverse transcriptase inhibitors
  • Observational study

Fingerprint Dive into the research topics of 'First-line antiretroviral therapy with efavirenz or lopinavir/ritonavir plus two nucleoside analogues: The SUSKA study, a non-randomized comparison from the VACH cohort'. Together they form a unique fingerprint.

Cite this